Pfizer pulls sickle cell treatment Oxbryta
Pfizer withdraws sickle-cell disease treatment
U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks of a painful complication and deaths.
Pfizer pulls sickle cell drug oxbryta, raising safety concerns
Pfizer’s abrupt withdrawal of Oxbryta, a drug for sickle cell disease, has sent shockwaves through the medical community.
Pfizer’s Strategy Looks Shakier After Sickle-Cell Disappointment
The company said it was withdrawing Oxbryta, a daily pill for patients with the disease, a serious, lifelong condition.
Pfizer to Withdraw Sickle Cell Drug Oxbryta Lots from World-Wide Markets
The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population.
Pfizer Recalls All of Its Sickle Cell Disease Treatment Over Safety Concerns
Pfizer is withdrawing all of its sickle cell disease drug, Oxbryta, worldwide because of safety concerns. Pfizer ( PFE) shares declined Thursday after the drug maker recalled all lots of its sickle cell disease medicine worldwide because of concerns it could lead to severe pain and possibly death in patients.
What the withdrawal of its sickle cell drug means for Pfizer, patients, and the FDA
Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and doctors, leaving many searching for answers and scrambling for ways to notify their patients about a drug that has long divided the community.
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say
Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
Pfizer yanks sickle-cell treatment worldwide after possible link to deaths
Pfizer Inc. said late Wednesday it was withdrawing a sickle-cell drug from markets worldwide and discontinuing clinical trials of the treatment after it investigates data suggesting a potential link to sickle-cell complications and “fatal events.”
Sickle cell community scrambles to find safe plan after a drug is pulled from the market
After Pfizer withdrew its sickle cell drug from the market, patients with the condition and their doctors were left scrambling to figure out what to do.
Pfizer to pull sickle cell drug from market, shut down trials
The withdrawal comes as trial results indicate safety concerns with the drug, Oxbryta, which was first approved in the U.S. in 2019.
Medscape5h
Pfizer's Withdrawal of SCD Drug Raises Questions
Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...
Pfizer starts voluntary withdraw of OXBRYTA, benefit does not outweigh risks
Pfizer withdraws OXBRYTA after post marketing studies showed that the risks of side effects were greater than the benefits.
Pfizer to Withdraw Sickle-Cell Drug Oxbryta From Worldwide Markets
The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...